We read with interest the article by Eads et al1 in a recent issue of the Archives on submitting fibroepithelial polyps for histological examination, and we welcome the publication of this information. Dermatologists will be better able to defend themselves against lawsuits should they choose to discard skin specimens and a malignancy ever develops in the vicinity of the initial surgery. One of us (R.T.B.) has been involved as an expert witness in such a case. However, we envision eager managed care plans that could twist the meaning of this study and create policies that restrict payment for lesions histologically proven to be fibroepithelial polyps. Of course, if the lesions are removed for cosmetic reasons, the managed care organization is absolved of responsibility for payment of both surgery and histopathologic work. However, if lesions are removed for medical indications, the pathologic examination in some circumstances is appropriate and should
Brodell RT, Pokorney DR. Fibroepithelial Polyps and Pathologic Evaluation. Arch Dermatol. 1997;133(7):915. doi:10.1001/archderm.1997.03890430137023
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: